TISIDB

Summary
Symbol	NLN
Name	neurolysin (metallopeptidase M3 family)
Aliases	KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location	5q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Mitochondrion intermembrane space Cytoplasm
Domain	PF01432 Peptidase family M3
Function	Hydrolyzes oligopeptides such as neurotensin, bradykinin and dynorphin A.

> Gene Ontology [ TOP ]
Biological Process	GO:0005996 monosaccharide metabolic process GO:0006006 glucose metabolic process GO:0006094 gluconeogenesis GO:0006109 regulation of carbohydrate metabolic process GO:0006111 regulation of gluconeogenesis GO:0007517 muscle organ development GO:0007519 skeletal muscle tissue development GO:0010675 regulation of cellular carbohydrate metabolic process GO:0010830 regulation of myotube differentiation GO:0010906 regulation of glucose metabolic process GO:0014706 striated muscle tissue development GO:0014902 myotube differentiation GO:0016051 carbohydrate biosynthetic process GO:0016202 regulation of striated muscle tissue development GO:0019318 hexose metabolic process GO:0019319 hexose biosynthetic process GO:0035914 skeletal muscle cell differentiation GO:0042692 muscle cell differentiation GO:0043255 regulation of carbohydrate biosynthetic process GO:0044262 cellular carbohydrate metabolic process GO:0044283 small molecule biosynthetic process GO:0044723 single-organism carbohydrate metabolic process GO:0046364 monosaccharide biosynthetic process GO:0048634 regulation of muscle organ development GO:0048641 regulation of skeletal muscle tissue development GO:0051146 striated muscle cell differentiation GO:0051147 regulation of muscle cell differentiation GO:0051153 regulation of striated muscle cell differentiation GO:0060537 muscle tissue development GO:0060538 skeletal muscle organ development GO:0098528 skeletal muscle fiber differentiation GO:1901861 regulation of muscle tissue development GO:1902809 regulation of skeletal muscle fiber differentiation GO:2001014 regulation of skeletal muscle cell differentiation
Molecular Function	GO:0004175 endopeptidase activity GO:0004222 metalloendopeptidase activity GO:0008237 metallopeptidase activity GO:0033218 amide binding GO:0042277 peptide binding
Cellular Component	GO:0005758 mitochondrial intermembrane space GO:0031970 organelle envelope lumen

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04614 Renin-angiotensin system
Reactome	R-HSA-373076: Class A/1 (Rhodopsin-like receptors) R-HSA-500792: GPCR ligand binding R-HSA-375276: Peptide ligand-binding receptors R-HSA-162582: Signal Transduction R-HSA-372790: Signaling by GPCR

Summary
Symbol	NLN
Name	neurolysin (metallopeptidase M3 family)
Aliases	KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location	5q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NLN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	NLN
Name	neurolysin (metallopeptidase M3 family)
Aliases	KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location	5q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NLN in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -1.05; FDR: 0.04630	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NLN
Name	neurolysin (metallopeptidase M3 family)
Aliases	KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location	5q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NLN in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.112	0.696
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.216	0.845
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.041	0.964
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.183	0.49
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.191	0.9
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.172	0.929
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.011	0.976
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.231	0.883
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.222	0.903
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.538	0.612
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.206	0.882
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.023	0.828

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NLN in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	NLN
Name	neurolysin (metallopeptidase M3 family)
Aliases	KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location	5q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NLN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NLN
Name	neurolysin (metallopeptidase M3 family)
Aliases	KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location	5q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NLN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NLN. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NLN
Name	neurolysin (metallopeptidase M3 family)
Aliases	KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location	5q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NLN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NLN
Name	neurolysin (metallopeptidase M3 family)
Aliases	KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location	5q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NLN expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NLN
Name	neurolysin (metallopeptidase M3 family)
Aliases	KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location	5q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NLN and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NLN
Name	neurolysin (metallopeptidase M3 family)
Aliases	KIAA1226; AGTBP; angiotensin binding protein; EP24.16; angiotensin-binding protein; endopeptidase 24.16; mic ......
Chromosomal Location	5q12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NLN collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse NLN